Cullinan Oncology/$CGEM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cullinan Oncology
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Ticker
$CGEM
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
111
ISIN
US2300311063
Website
CGEM Metrics
BasicAdvanced
$463M
-
-$3.10
-0.07
-
Price and volume
Market cap
$463M
Beta
-0.07
52-week high
$21.01
52-week low
$6.85
Average daily volume
371K
Financial strength
Current ratio
11.619
Quick ratio
20.747
Long term debt to equity
0.089
Total debt to equity
0.333
Profitability
EBITDA (TTM)
-208.62
Effective tax rate (TTM)
-0.07%
Management effectiveness
Return on assets (TTM)
-25.38%
Return on equity (TTM)
-36.57%
Valuation
Price to book
0.83
Price to tangible book (TTM)
0.83
Price to free cash flow (TTM)
-3.014
Free cash flow yield (TTM)
-33.18%
Free cash flow per share (TTM)
-260.13%
Growth
Earnings per share change (TTM)
-1.46%
3-year earnings per share growth (CAGR)
20.34%
What the Analysts think about CGEM
Analyst ratings (Buy, Hold, Sell) for Cullinan Oncology stock.
Bulls say / Bears say
Cullinan Therapeutics' strategic pivot to autoimmune diseases, particularly with CLN-978 targeting systemic lupus erythematosus, positions the company in a growing market with significant unmet needs. (biopharmadive.com)
The successful $280 million private placement enhances Cullinan's financial stability, extending its cash runway into 2028 and supporting ongoing development programs. (benzinga.com)
Positive Phase 2b REZILIENT1 trial results for zipalertinib in non-small cell lung cancer patients, showing a 40% objective response rate, demonstrate the potential of Cullinan's oncology pipeline. (investing.com)
The discontinuation of the B cell non-Hodgkin lymphoma study to focus on autoimmune indications may raise concerns about the company's commitment to its oncology pipeline. (fiercebiotech.com)
Morgan Stanley's reduction of Cullinan's price target to $38, citing disappointing results, reflects potential challenges in meeting market expectations. (investing.com)
The company's net loss increased to $48.5 million in Q1 2025 from $37.1 million in Q1 2024, indicating rising operational expenses that could impact financial sustainability. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CGEM Financial Performance
Revenues and expenses
CGEM Earnings Performance
Company profitability
CGEM News
AllArticlesVideos
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
GlobeNewsWire·1 month ago
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
GlobeNewsWire·1 month ago
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cullinan Oncology stock?
Cullinan Oncology (CGEM) has a market cap of $463M as of July 11, 2025.
What is the P/E ratio for Cullinan Oncology stock?
The price to earnings (P/E) ratio for Cullinan Oncology (CGEM) stock is 0 as of July 11, 2025.
Does Cullinan Oncology stock pay dividends?
No, Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Cullinan Oncology dividend payment date?
Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders.
What is the beta indicator for Cullinan Oncology?
Cullinan Oncology (CGEM) has a beta rating of -0.07. This means that it has an inverse relation to market volatility.